Literature DB >> 16331755

Lipid profiles among US elderly with untreated rheumatoid arthritis--the Third National Health and Nutrition Examination Survey.

Hyon K Choi1, John D Seeger.   

Abstract

OBJECTIVE: Recent studies suggest that patients with active rheumatoid arthritis (RA) have adverse serum lipid profiles. We examined lipid profiles among individuals with RA in a national sample of persons aged 60 years and older.
METHODS: Using data from 4862 participants (2379 men and 2483 women) aged 60 years and older in the Third National Health and Nutrition Examination Survey (1988-94), we examined lipid profiles among participants with RA who met the American College of Rheumatology (ACR) 1987 criteria and who were not taking glucocorticoids or disease modifying antirheumatic drugs (DMARD).
RESULTS: Participants with RA had lower high density lipoprotein cholesterol (HDL-C) and apolipoprotein A-I concentrations than those without RA. After adjusting for age and sex, the differences in HDL-C level between those with and those without RA were 2.5 mg/dl (95% CI 0.8 to 4.9) using > or = 3 of the ACR criteria (n of RA cases = 104) and 8.8 mg/dl (95% CI 3.2 to 14.3) using > or = 4 criteria (n of RA cases = 26). Adjusting for age, sex, race, education, smoking status, body mass index, alcohol consumption, physical activity, dietary factors, and other potential confounders attenuated the differences slightly. The multivariate difference in serum apolipoprotein A-I levels between those with and those without RA was 4.5 mg/dl (95% CI -0.8 to 9.8) using > or = 3 ACR criteria and 13.6 mg/dl (95% CI 3.2 to 24.1) using > or = 4 criteria. All individual RA disease activity measures tended to have inverse relations with HDL-C levels, but significant inverse associations were present only with the following variables: C-reactive protein [CRP; multivariate difference per 1 mg/dl of CRP, -1.3 mg/dl (95% CI -2.0 to -0.5)], presence of hand arthritis [-2.6 mg/dl (95% CI -5.0 to -0.2)], and positive rheumatoid factor [-3.4 mg/dl (95% CI -5.5 to -1.3)].
CONCLUSION: These national survey data indicate that RA not treated with DMARD or glucocorticoids is associated with adverse lipid profiles characterized by lower HDL-C and apolipoprotein A-I levels in persons aged > or = 60 years.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16331755

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  33 in total

1.  Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion.

Authors:  Inge A M van den Oever; Alper M van Sijl; Michael T Nurmohamed
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-08       Impact factor: 5.346

Review 2.  Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis.

Authors:  Katherine P Liao; Daniel H Solomon
Journal:  Rheumatology (Oxford)       Date:  2012-09-16       Impact factor: 7.580

3.  Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity.

Authors:  Daniel H Solomon; Joel Kremer; Jeffrey R Curtis; Marc C Hochberg; George Reed; Peter Tsao; Michael E Farkouh; Soko Setoguchi; Jeffrey D Greenberg
Journal:  Ann Rheum Dis       Date:  2010-05-05       Impact factor: 19.103

Review 4.  Prevention of Stroke in Rheumatoid Arthritis.

Authors:  Alicia M Zha; Mario Di Napoli; Réza Behrouz
Journal:  Curr Neurol Neurosci Rep       Date:  2015-12       Impact factor: 5.081

5.  A comparative analysis of serological parameters and oxidative stress in osteoarthritis and rheumatoid arthritis.

Authors:  Rachana Mishra; Aastha Singh; Vishal Chandra; Mahendra P S Negi; Baishnab C Tripathy; Jaya Prakash; Varsha Gupta
Journal:  Rheumatol Int       Date:  2011-06-05       Impact factor: 2.631

6.  Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis.

Authors:  Shin-ya Kawashiri; Atsushi Kawakami; Satoshi Yamasaki; Takahiro Imazato; Naoki Iwamoto; Keita Fujikawa; Toshiyuki Aramaki; Mami Tamai; Hideki Nakamura; Hiroaki Ida; Tomoki Origuchi; Yukitaka Ueki; Katsumi Eguchi
Journal:  Rheumatol Int       Date:  2009-12-19       Impact factor: 2.631

7.  Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis.

Authors:  Calin Popa; Frank H J van den Hoogen; Timothy R D J Radstake; Mihai G Netea; Agnes E Eijsbouts; Martin den Heijer; Jos W M van der Meer; Piet L C M van Riel; Anton F H Stalenhoef; Pilar Barrera
Journal:  Ann Rheum Dis       Date:  2007-05-01       Impact factor: 19.103

Review 8.  Inflammation, lipid metabolism and cardiovascular risk in rheumatoid arthritis: A qualitative relationship?

Authors:  Carmen García-Gómez; Maria Bianchi; Diana de la Fuente; Lina Badimon; Teresa Padró; Emili Corbella; Xavier Pintó
Journal:  World J Orthop       Date:  2014-07-18

9.  Total cholesterol and LDL levels decrease before rheumatoid arthritis.

Authors:  Elena Myasoedova; Cynthia S Crowson; Hilal Maradit Kremers; Patrick D Fitz-Gibbon; Terry M Therneau; Sherine E Gabriel
Journal:  Ann Rheum Dis       Date:  2009-10-23       Impact factor: 19.103

10.  Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60- more than just an anti-inflammatory effect? A cross sectional study.

Authors:  Tracey E Toms; Vasileios F Panoulas; Holly John; Karen M J Douglas; George D Kitas
Journal:  Arthritis Res Ther       Date:  2009-07-16       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.